多模态人工智能预测阿比特龙在非转移性极高危前列腺癌中的疗效:两项STAMPEDE III期试验分析
本研究基于STAMPEDE平台两项序贯阿比特龙试验(无共享对照)的1137例非转移性极高危前列腺癌患者,使用数字病理多模态人工智能(MMAI)模型预测阿比特龙获益。结果显示MMAI极高危组(N=268)加用阿比特龙显著改善无转移生存(HR 0.47,95%CI 0.31-0.70),5年MFS从62%升至81%;而MMAI标准高危组(N=869)获益有限(HR 0.83,95%CI 0.63-1.09),交互P=0.02。该生物标志物有望优化治疗强度选择。
要点
- MMAI极高危组加用阿比特龙显著改善MFS(HR 0.47,95%CI 0.31-0.70)。
- MMAI标准高危组阿比特龙获益有限(HR 0.83,95%CI 0.63-1.09),交互P=0.02。
- MMAI模型可辅助筛选从阿比特龙治疗中获益的极高危患者。
核心结论
- 在非转移性极高危前列腺癌中,MMAI检测显示强预后关联并预测阿比特龙疗效。
- 该生物标志物可用于临床最大化治疗强化获益并避免不必要的毒性。
研究设计与样本
- 研究为对两项随机临床试验数据的事后分析,纳入STAMPEDE平台协议(NCT00268476)中1137例患者。
- 患者随机分配至长期雄激素剥夺治疗(LT-ADT,N=583)或LT-ADT联合阿比特龙(N=554)。
- MMAI评分基于数字病理图像、前列腺特异性抗原、肿瘤分期和年龄生成,采用预设的75百分位阈值分类。
主要发现
- MMAI极高危组(N=268)加用阿比特龙显著改善MFS(HR 0.47,95%CI 0.31-0.70),5年MFS从62%(95%CI 54%-70%)升至81%(95%CI 74%-88%)。
- MMAI标准高危组(N=869)阿比特龙获益有限(HR 0.83,95%CI 0.63-1.09),5年MFS为82%(95%CI 78%-85%)对84%(95%CI 80%-87%),交互P=0.02。
- 该差异效应在局部淋巴结阴性和阳性亚组中一致。
临床怎么用
- MMAI检测可用于识别非转移性极高危前列腺癌中可能从阿比特龙治疗中显著获益的患者。
- 对MMAI标准高危患者,加用阿比特龙的获益有限,可考虑避免不必要的治疗毒性。
局限性
- 本研究为事后分析,需前瞻性验证。
- 两项试验无共享对照,可能影响比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Long-term androgen deprivation therapy (LT-ADT) with radiotherapy is standard-of-care for high-risk localized prostate cancer, with abiraterone added for clinically very high-risk disease. Given the potential toxicity and cost of abiraterone, a predictive biomarker to refine patient selection is needed. We evaluated a digital pathology multimodal artificial intelligence (MMAI) model, previously validated as a prognostic biomarker, for prediction of abiraterone benefit among nonmetastatic clinically very high-risk prostate cancer. PATIENTS AND METHODS: MMAI scores were generated for patients enrolled in two sequential abiraterone trials (no shared controls) in the STAMPEDE (Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy) platform protocol (NCT00268476) using digital pathology images, prostate-specific antigen, tumor stage, and age. We applied the previously established 75th percentile threshold to classify patients as MMAI very high-risk or standard high-risk. The primary endpoint was metastasis-free survival (MFS). Treatment effects and risk estimates were obtained using Cox regression and Kaplan-Meier method, respectively. Prediction was assessed using a treatment-by-biomarker interaction Cox model. RESULTS: In total, 1137 patients randomly assigned to LT-ADT (N = 583) or LT-ADT with abiraterone (N = 554) were included. The MMAI very high-risk group (N = 268) demonstrated significant MFS improvement from adding abiraterone [hazard ratio (HR) 0.47, 95% confidence interval (CI) 0.31-0.70], with 5-year MFS increasing from 62% (95% CI 54% to 70%) in LT-ADT to 81% (95% CI 74% to 88%) in LT-ADT with abiraterone. Limited abiraterone benefit was observed in the MMAI standard high-risk group (N = 869; HR 0.83, 95% CI 0.63-1.09), with a 5-year MFS of 82% (95% CI 78% to 85%) versus 84% (95% CI 80% to 87%, interaction P-value = 0.02). This differential effect was consistent in local node-negative and node-positive subgroups. CONCLUSION: In this post hoc study of randomized clinical trial data, a locked digital pathology MMAI test displayed a strong prognostic association and predicted abiraterone efficacy in very high-risk, nonmetastatic prostate cancer. This biomarker could be implemented clinically to maximize benefit from treatment intensification while avoiding unnecessary toxicity.
引用
- Parker CTA, Huang HC, Grist E, et al. Multimodal artificial intelligence prediction of abiraterone efficacy in two STAMPEDE phase III trials of nonmetastatic very high-risk prostate cancer. Ann Oncol. 2026. PMID: 42250604. doi:10.1016/j.annonc.2026.05.708
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。